229 related articles for article (PubMed ID: 21663843)
1. Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity.
Cotter AG; Powderly WG
Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):501-15. PubMed ID: 21663843
[TBL] [Abstract][Full Text] [Related]
2. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy.
Parsonage MJ; Wilkins EG; Snowden N; Issa BG; Savage MW
HIV Med; 2005 Sep; 6(5):341-6. PubMed ID: 16156882
[TBL] [Abstract][Full Text] [Related]
3. Nephrolithiasis and hydronephrosis in an HIV-infected man receiving tenofovir.
Cicconi P; Bongiovanni M; Melzi S; Tordato F; d'Arminio Monforte A; Bini T
Int J Antimicrob Agents; 2004 Sep; 24(3):284-5. PubMed ID: 15325433
[TBL] [Abstract][Full Text] [Related]
4. The role of HIV and antiretroviral therapy in bone disease.
Gutiérrez F; Masiá M
AIDS Rev; 2011; 13(2):109-18. PubMed ID: 21587342
[TBL] [Abstract][Full Text] [Related]
5. Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient.
Perrot S; Aslangul E; Szwebel T; Caillat-Vigneron N; Le Jeunne C
J Clin Rheumatol; 2009 Mar; 15(2):72-4. PubMed ID: 19265350
[TBL] [Abstract][Full Text] [Related]
6. Renal toxicity associated with tenofovir use.
Rodriguez-Nóvoa S; Alvarez E; Labarga P; Soriano V
Expert Opin Drug Saf; 2010 Jul; 9(4):545-59. PubMed ID: 20384533
[TBL] [Abstract][Full Text] [Related]
7. Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.
Psevdos G; Gonzalez E; Sharp V
AIDS Read; 2009; 19(6):245-8. PubMed ID: 19642243
[TBL] [Abstract][Full Text] [Related]
8. Bone disease and pathologic fractures in a patient with tenofovir-induced Fanconi syndrome.
Brim NM; Cu-Uvin S; Hu SL; O'Bell JW
AIDS Read; 2007 Jun; 17(6):322-8, C3. PubMed ID: 17632940
[TBL] [Abstract][Full Text] [Related]
9. Osteoporosis and bone health in HIV.
Powderly WG
Curr HIV/AIDS Rep; 2012 Sep; 9(3):218-22. PubMed ID: 22581359
[TBL] [Abstract][Full Text] [Related]
10. HIV infection and bone disease: implications for an aging population.
Cotter AG; Mallon PW
Sex Health; 2011 Dec; 8(4):493-501. PubMed ID: 22127034
[TBL] [Abstract][Full Text] [Related]
11. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B.
Mauss S; Berger F; Filmann N; Hueppe D; Henke J; Hegener P; Athmann C; Schmutz G; Herrmann E
J Hepatol; 2011 Dec; 55(6):1235-40. PubMed ID: 21703180
[TBL] [Abstract][Full Text] [Related]
12. Bone disorders in human immunodeficiency virus infection.
Glesby MJ
Clin Infect Dis; 2003; 37 Suppl 2():S91-5. PubMed ID: 12942380
[TBL] [Abstract][Full Text] [Related]
13. The art of managing human immunodeficiency virus infection: a balancing act.
Reiss P
Clin Infect Dis; 2009 Nov; 49(10):1602-4. PubMed ID: 19842978
[No Abstract] [Full Text] [Related]
14. Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function.
Rosso R; Nasi M; Di Biagio A; Repetto E; Dentone C; Pinti M; Nemes E; Ferraresi R; Mussini C; Esposito R; Viscoli C; Cossarizza A
Pediatr Infect Dis J; 2008 Jan; 27(1):17-21. PubMed ID: 18162932
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir and changes in renal function.
Gupta SK
Clin Infect Dis; 2005 Aug; 41(4):570-1; author reply 571. PubMed ID: 16028175
[No Abstract] [Full Text] [Related]
16. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
Martin A; Bloch M; Amin J; Baker D; Cooper DA; Emery S; Carr A
Clin Infect Dis; 2009 Nov; 49(10):1591-601. PubMed ID: 19842973
[TBL] [Abstract][Full Text] [Related]
17. Adverse effects of tenofovir use in HIV-infected pregnant women and their infants.
Nurutdinova D; Onen NF; Hayes E; Mondy K; Overton ET
Ann Pharmacother; 2008 Nov; 42(11):1581-5. PubMed ID: 18957630
[TBL] [Abstract][Full Text] [Related]
18. Temporal changes in renal glomerular function associated with the use of Tenofovir Disoproxil Fumarate in HIV-infected Nigerians.
Agbaji OO; Agaba PA; Idoko JA; Taiwo B; Murphy R; Kanki P; Ekong E
West Afr J Med; 2011; 30(3):164-8. PubMed ID: 22120479
[TBL] [Abstract][Full Text] [Related]
19. A randomized study of tenofovir disoproxil fumarate in treatment-experienced HIV-1 infected adolescents.
Della Negra M; de Carvalho AP; de Aquino MZ; da Silva MT; Pinto J; White K; Arterburn S; Liu YP; Enejosa JV; Cheng AK; Chuck SL; Rhee MS
Pediatr Infect Dis J; 2012 May; 31(5):469-73. PubMed ID: 22301477
[TBL] [Abstract][Full Text] [Related]
20. Improvement of dyslipidemia during different HAART regimens: tenofovir- versus stavudine-containing antiretroviral combinations.
Manfredi R
Clin Infect Dis; 2006 May; 42(9):1345-7; author reply 1347-8. PubMed ID: 16586399
[No Abstract] [Full Text] [Related]
[Next] [New Search]
